title: Report on the Eleventh International Society of Blood Transfusion Platelet Genotyping and Serology Workshop.
abstract: OBJECTIVE
  The aims of the Eleventh International Workshop were to evaluate proficiency in platelet genotyping and antibody detection, to equip laboratories to perform Gov antigen system genotyping and antibody detection, and to evaluate the laboratory and clinical approach to cases of neonatal alloimmune thrombocytopenia (NAIT).
  
  
  METHODS
  There were 34 participating laboratories from 22 countries on five continents. Participating laboratories were provided with 10 DNA samples, 15 unknown sera, and three monoclonal antibodies for titration, as well as primer pairs and a protocol for Gov genotyping and Gov antibody screening. They were also provided with a questionnaire on investigation and clinical management of patients with NAIT.
  
  
  RESULTS
  Thirty-three participants reported human platelet antigen (HPA)-1, -2, -3 and -5 genotyping results, 25 reported HPA-4 typing results, 17 reported HPA-6 typing results and 24 reported Gov typing results. For HPA-1-6 genotyping, 23 laboratories were concordant with a majority vote for all allotypes tested, five laboratories reported one deviation, three laboratories reported two deviations and one laboratory reported three deviations. For Gov genotyping, six deviations occurred in three of the 24 laboratories reporting results. Antibody detection was 90% concordant for anti-HPA-1a, anti-HPA-5a and anti-HPA-5b detection. Anti-HPA-2b and anti-Gova were detected by 20 and 14 out of 33 laboratories, respectively. Approaches to the clinical management of NAIT vary widely, especially for mothers with a history of a previous infant with mild NAIT.
  
  
  CONCLUSIONS
  The overall error rate for HPA-1-6 genotyping decreased from 2.7% in the tenth workshop to 0.8% in the eleventh workshop. The majority of laboratories were able to perform Gov genotyping, although the error rate was 7.5%. Detection of common clinically significant antibodies was good, although detection of the much rarer HPA-2b was problematic. There was considerable progress in the detection of anti-Gova. The lack of consensus over treatment of NAIT demonstrates uncertainty over optimal management of these patients.
authors.affiliation: Hospital Services Laboratory, Héma-Québec, Montreal, Quebec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Goldman
authors.forename: E
authors.initials: E
authors.lastname: Trudel
authors.forename: L
authors.initials: L
authors.lastname: Richard
mesh_terms: D016824:Antigens, Human Platelet / Q000235:genetics*; D001803:Blood Transfusion / Q000592:standards*; D019411:Clinical Laboratory Techniques / Q000592:standards; D005838:Genotype; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D007753:Laboratories / Q000592:standards; D019300:Medical Errors; D012955:Societies, Medical
chemical_list: D016824:Antigens, Human Platelet; D007518:Isoantibodies